nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—type 2 diabetes mellitus—obesity	0.377	0.583	CtDrD
Valsartan—hypertension—obesity	0.269	0.417	CtDrD
Valsartan—ALB—obesity	0.111	1	CbGaD
Valsartan—CYP2C9—Phentermine—obesity	0.0297	0.404	CbGbCtD
Valsartan—CYP2C9—Bupropion—obesity	0.0252	0.344	CbGbCtD
Valsartan—CYP2C9—Cimetidine—obesity	0.0185	0.252	CbGbCtD
Valsartan—ALB—gall bladder—obesity	0.000618	0.103	CbGeAlD
Valsartan—SLCO1B3—pituitary gland—obesity	0.000554	0.0922	CbGeAlD
Valsartan—SLCO1B3—endocrine gland—obesity	0.000429	0.0714	CbGeAlD
Valsartan—AGTR1—adrenal cortex—obesity	0.000416	0.0692	CbGeAlD
Valsartan—SLCO1B3—liver—obesity	0.000387	0.0644	CbGeAlD
Valsartan—AGTR1—cardiovascular system—obesity	0.00038	0.0632	CbGeAlD
Valsartan—AGTR1—pituitary gland—obesity	0.000336	0.0559	CbGeAlD
Valsartan—AGTR1—adipose tissue—obesity	0.000335	0.0557	CbGeAlD
Valsartan—SLCO1B1—digestive system—obesity	0.0003	0.05	CbGeAlD
Valsartan—AGTR1—adrenal gland—obesity	0.0003	0.05	CbGeAlD
Valsartan—AGTR1—endocrine gland—obesity	0.00026	0.0433	CbGeAlD
Valsartan—SLCO1B1—endocrine gland—obesity	0.000248	0.0413	CbGeAlD
Valsartan—AGTR1—liver—obesity	0.000235	0.0391	CbGeAlD
Valsartan—ALB—adrenal gland—obesity	0.000232	0.0386	CbGeAlD
Valsartan—SLCO1B1—liver—obesity	0.000224	0.0373	CbGeAlD
Valsartan—Immune system disorder—Orlistat—obesity	0.000208	0.00224	CcSEcCtD
Valsartan—Mediastinal disorder—Orlistat—obesity	0.000208	0.00224	CcSEcCtD
Valsartan—Dizziness—Diethylpropion—obesity	0.000206	0.00222	CcSEcCtD
Valsartan—Epistaxis—Bupropion—obesity	0.000204	0.0022	CcSEcCtD
Valsartan—Alopecia—Orlistat—obesity	0.000203	0.00219	CcSEcCtD
Valsartan—Sinusitis—Bupropion—obesity	0.000203	0.00219	CcSEcCtD
Valsartan—Diarrhoea—Cimetidine—obesity	0.000203	0.00218	CcSEcCtD
Valsartan—Angiopathy—Sibutramine—obesity	0.000202	0.00218	CcSEcCtD
Valsartan—Mental disorder—Orlistat—obesity	0.000202	0.00217	CcSEcCtD
Valsartan—Immune system disorder—Sibutramine—obesity	0.000201	0.00217	CcSEcCtD
Valsartan—Malnutrition—Orlistat—obesity	0.0002	0.00216	CcSEcCtD
Valsartan—Vomiting—Diethylpropion—obesity	0.000198	0.00213	CcSEcCtD
Valsartan—Flatulence—Orlistat—obesity	0.000198	0.00213	CcSEcCtD
Valsartan—Alopecia—Sibutramine—obesity	0.000197	0.00212	CcSEcCtD
Valsartan—Rash—Diethylpropion—obesity	0.000196	0.00212	CcSEcCtD
Valsartan—Dysgeusia—Orlistat—obesity	0.000196	0.00211	CcSEcCtD
Valsartan—Dermatitis—Diethylpropion—obesity	0.000196	0.00211	CcSEcCtD
Valsartan—Dizziness—Cimetidine—obesity	0.000196	0.00211	CcSEcCtD
Valsartan—Haemoglobin—Bupropion—obesity	0.000195	0.0021	CcSEcCtD
Valsartan—Headache—Diethylpropion—obesity	0.000195	0.0021	CcSEcCtD
Valsartan—Rhinitis—Bupropion—obesity	0.000195	0.0021	CcSEcCtD
Valsartan—Haemorrhage—Bupropion—obesity	0.000194	0.00209	CcSEcCtD
Valsartan—Hepatitis—Bupropion—obesity	0.000194	0.00209	CcSEcCtD
Valsartan—Malnutrition—Sibutramine—obesity	0.000194	0.00209	CcSEcCtD
Valsartan—Back pain—Orlistat—obesity	0.000194	0.00209	CcSEcCtD
Valsartan—Pharyngitis—Bupropion—obesity	0.000193	0.00208	CcSEcCtD
Valsartan—Muscle spasms—Orlistat—obesity	0.000193	0.00208	CcSEcCtD
Valsartan—Urinary tract disorder—Bupropion—obesity	0.000192	0.00207	CcSEcCtD
Valsartan—Flatulence—Sibutramine—obesity	0.000191	0.00206	CcSEcCtD
Valsartan—Connective tissue disorder—Bupropion—obesity	0.000191	0.00206	CcSEcCtD
Valsartan—Urethral disorder—Bupropion—obesity	0.00019	0.00205	CcSEcCtD
Valsartan—Dysgeusia—Sibutramine—obesity	0.00019	0.00205	CcSEcCtD
Valsartan—Vision blurred—Orlistat—obesity	0.000189	0.00204	CcSEcCtD
Valsartan—Vomiting—Cimetidine—obesity	0.000188	0.00203	CcSEcCtD
Valsartan—Back pain—Sibutramine—obesity	0.000188	0.00202	CcSEcCtD
Valsartan—Rash—Cimetidine—obesity	0.000187	0.00201	CcSEcCtD
Valsartan—Dermatitis—Cimetidine—obesity	0.000187	0.00201	CcSEcCtD
Valsartan—Muscle spasms—Sibutramine—obesity	0.000187	0.00201	CcSEcCtD
Valsartan—Headache—Cimetidine—obesity	0.000186	0.002	CcSEcCtD
Valsartan—Nausea—Diethylpropion—obesity	0.000185	0.00199	CcSEcCtD
Valsartan—Angioedema—Orlistat—obesity	0.000183	0.00197	CcSEcCtD
Valsartan—Vision blurred—Sibutramine—obesity	0.000183	0.00197	CcSEcCtD
Valsartan—CYP2C9—cardiovascular system—obesity	0.000183	0.0304	CbGeAlD
Valsartan—ALB—liver—obesity	0.000181	0.0301	CbGeAlD
Valsartan—Cardiac disorder—Bupropion—obesity	0.00018	0.00194	CcSEcCtD
Valsartan—Vertigo—Orlistat—obesity	0.00018	0.00194	CcSEcCtD
Valsartan—Hyponatraemia—Topiramate—obesity	0.00018	0.00194	CcSEcCtD
Valsartan—Angioedema—Sibutramine—obesity	0.000177	0.00191	CcSEcCtD
Valsartan—Palpitations—Orlistat—obesity	0.000177	0.00191	CcSEcCtD
Valsartan—Angiopathy—Bupropion—obesity	0.000176	0.0019	CcSEcCtD
Valsartan—Nausea—Cimetidine—obesity	0.000176	0.0019	CcSEcCtD
Valsartan—Immune system disorder—Bupropion—obesity	0.000175	0.00189	CcSEcCtD
Valsartan—Mediastinal disorder—Bupropion—obesity	0.000175	0.00189	CcSEcCtD
Valsartan—Cough—Orlistat—obesity	0.000175	0.00188	CcSEcCtD
Valsartan—Vertigo—Sibutramine—obesity	0.000174	0.00188	CcSEcCtD
Valsartan—Syncope—Sibutramine—obesity	0.000174	0.00187	CcSEcCtD
Valsartan—Alopecia—Bupropion—obesity	0.000172	0.00185	CcSEcCtD
Valsartan—Palpitations—Sibutramine—obesity	0.000171	0.00185	CcSEcCtD
Valsartan—Myalgia—Orlistat—obesity	0.000171	0.00184	CcSEcCtD
Valsartan—Chest pain—Orlistat—obesity	0.000171	0.00184	CcSEcCtD
Valsartan—Loss of consciousness—Sibutramine—obesity	0.000171	0.00184	CcSEcCtD
Valsartan—Mental disorder—Bupropion—obesity	0.00017	0.00183	CcSEcCtD
Valsartan—Anxiety—Orlistat—obesity	0.00017	0.00183	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000169	0.00183	CcSEcCtD
Valsartan—Cough—Sibutramine—obesity	0.000169	0.00182	CcSEcCtD
Valsartan—Malnutrition—Bupropion—obesity	0.000169	0.00182	CcSEcCtD
Valsartan—Blood creatinine increased—Topiramate—obesity	0.000168	0.00181	CcSEcCtD
Valsartan—Dry mouth—Orlistat—obesity	0.000167	0.0018	CcSEcCtD
Valsartan—Flatulence—Bupropion—obesity	0.000167	0.0018	CcSEcCtD
Valsartan—Dysgeusia—Bupropion—obesity	0.000166	0.00178	CcSEcCtD
Valsartan—Chest pain—Sibutramine—obesity	0.000165	0.00178	CcSEcCtD
Valsartan—Arthralgia—Sibutramine—obesity	0.000165	0.00178	CcSEcCtD
Valsartan—Myalgia—Sibutramine—obesity	0.000165	0.00178	CcSEcCtD
Valsartan—Anxiety—Sibutramine—obesity	0.000165	0.00177	CcSEcCtD
Valsartan—Oedema—Orlistat—obesity	0.000164	0.00176	CcSEcCtD
Valsartan—Anaphylactic shock—Orlistat—obesity	0.000164	0.00176	CcSEcCtD
Valsartan—Back pain—Bupropion—obesity	0.000164	0.00176	CcSEcCtD
Valsartan—Abdominal pain upper—Topiramate—obesity	0.000163	0.00176	CcSEcCtD
Valsartan—Orthostatic hypotension—Topiramate—obesity	0.000163	0.00176	CcSEcCtD
Valsartan—Muscle spasms—Bupropion—obesity	0.000163	0.00175	CcSEcCtD
Valsartan—Infection—Orlistat—obesity	0.000163	0.00175	CcSEcCtD
Valsartan—Dry mouth—Sibutramine—obesity	0.000162	0.00174	CcSEcCtD
Valsartan—Nervous system disorder—Orlistat—obesity	0.00016	0.00173	CcSEcCtD
Valsartan—Vision blurred—Bupropion—obesity	0.000159	0.00172	CcSEcCtD
Valsartan—Skin disorder—Orlistat—obesity	0.000159	0.00171	CcSEcCtD
Valsartan—Anaphylactic shock—Sibutramine—obesity	0.000158	0.00171	CcSEcCtD
Valsartan—Oedema—Sibutramine—obesity	0.000158	0.00171	CcSEcCtD
Valsartan—Muscular weakness—Topiramate—obesity	0.000158	0.0017	CcSEcCtD
Valsartan—Infection—Sibutramine—obesity	0.000157	0.00169	CcSEcCtD
Valsartan—Shock—Sibutramine—obesity	0.000156	0.00168	CcSEcCtD
Valsartan—Thrombocytopenia—Sibutramine—obesity	0.000155	0.00167	CcSEcCtD
Valsartan—Angioedema—Bupropion—obesity	0.000155	0.00166	CcSEcCtD
Valsartan—Skin disorder—Sibutramine—obesity	0.000154	0.00166	CcSEcCtD
Valsartan—Vertigo—Bupropion—obesity	0.000152	0.00164	CcSEcCtD
Valsartan—CYP2C9—digestive system—obesity	0.000152	0.0253	CbGeAlD
Valsartan—Syncope—Bupropion—obesity	0.000152	0.00163	CcSEcCtD
Valsartan—Anorexia—Sibutramine—obesity	0.000151	0.00163	CcSEcCtD
Valsartan—Palpitations—Bupropion—obesity	0.000149	0.00161	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Orlistat—obesity	0.000149	0.00161	CcSEcCtD
Valsartan—Bronchitis—Topiramate—obesity	0.000149	0.0016	CcSEcCtD
Valsartan—Loss of consciousness—Bupropion—obesity	0.000149	0.0016	CcSEcCtD
Valsartan—Insomnia—Orlistat—obesity	0.000148	0.00159	CcSEcCtD
Valsartan—Hypotension—Sibutramine—obesity	0.000148	0.00159	CcSEcCtD
Valsartan—Cough—Bupropion—obesity	0.000148	0.00159	CcSEcCtD
Valsartan—Paraesthesia—Orlistat—obesity	0.000147	0.00158	CcSEcCtD
Valsartan—Neutropenia—Topiramate—obesity	0.000145	0.00156	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Sibutramine—obesity	0.000144	0.00155	CcSEcCtD
Valsartan—Dyspepsia—Orlistat—obesity	0.000144	0.00155	CcSEcCtD
Valsartan—Arthralgia—Bupropion—obesity	0.000144	0.00155	CcSEcCtD
Valsartan—Chest pain—Bupropion—obesity	0.000144	0.00155	CcSEcCtD
Valsartan—Myalgia—Bupropion—obesity	0.000144	0.00155	CcSEcCtD
Valsartan—Upper respiratory tract infection—Topiramate—obesity	0.000144	0.00155	CcSEcCtD
Valsartan—Anxiety—Bupropion—obesity	0.000143	0.00155	CcSEcCtD
Valsartan—Insomnia—Sibutramine—obesity	0.000143	0.00154	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000143	0.00154	CcSEcCtD
Valsartan—Erectile dysfunction—Topiramate—obesity	0.000142	0.00153	CcSEcCtD
Valsartan—Decreased appetite—Orlistat—obesity	0.000142	0.00153	CcSEcCtD
Valsartan—Paraesthesia—Sibutramine—obesity	0.000142	0.00153	CcSEcCtD
Valsartan—Gastrointestinal disorder—Orlistat—obesity	0.000141	0.00152	CcSEcCtD
Valsartan—Dyspnoea—Sibutramine—obesity	0.000141	0.00152	CcSEcCtD
Valsartan—Photosensitivity reaction—Topiramate—obesity	0.000141	0.00152	CcSEcCtD
Valsartan—Fatigue—Orlistat—obesity	0.000141	0.00152	CcSEcCtD
Valsartan—Dry mouth—Bupropion—obesity	0.000141	0.00152	CcSEcCtD
Valsartan—Somnolence—Sibutramine—obesity	0.000141	0.00152	CcSEcCtD
Valsartan—Dyspepsia—Sibutramine—obesity	0.000139	0.0015	CcSEcCtD
Valsartan—Oedema—Bupropion—obesity	0.000138	0.00149	CcSEcCtD
Valsartan—Anaphylactic shock—Bupropion—obesity	0.000138	0.00149	CcSEcCtD
Valsartan—Infestation NOS—Topiramate—obesity	0.000138	0.00149	CcSEcCtD
Valsartan—Infestation—Topiramate—obesity	0.000138	0.00149	CcSEcCtD
Valsartan—Decreased appetite—Sibutramine—obesity	0.000138	0.00148	CcSEcCtD
Valsartan—Infection—Bupropion—obesity	0.000137	0.00148	CcSEcCtD
Valsartan—Gastrointestinal disorder—Sibutramine—obesity	0.000137	0.00147	CcSEcCtD
Valsartan—Shock—Bupropion—obesity	0.000136	0.00146	CcSEcCtD
Valsartan—Renal failure—Topiramate—obesity	0.000136	0.00146	CcSEcCtD
Valsartan—Constipation—Sibutramine—obesity	0.000135	0.00146	CcSEcCtD
Valsartan—Nervous system disorder—Bupropion—obesity	0.000135	0.00146	CcSEcCtD
Valsartan—Thrombocytopenia—Bupropion—obesity	0.000135	0.00146	CcSEcCtD
Valsartan—Skin disorder—Bupropion—obesity	0.000134	0.00144	CcSEcCtD
Valsartan—Gastrointestinal pain—Orlistat—obesity	0.000134	0.00144	CcSEcCtD
Valsartan—Anorexia—Bupropion—obesity	0.000132	0.00142	CcSEcCtD
Valsartan—Epistaxis—Topiramate—obesity	0.00013	0.0014	CcSEcCtD
Valsartan—Urticaria—Orlistat—obesity	0.00013	0.0014	CcSEcCtD
Valsartan—Gastrointestinal pain—Sibutramine—obesity	0.000129	0.00139	CcSEcCtD
Valsartan—Sinusitis—Topiramate—obesity	0.000129	0.00139	CcSEcCtD
Valsartan—Abdominal pain—Orlistat—obesity	0.000129	0.00139	CcSEcCtD
Valsartan—Hypotension—Bupropion—obesity	0.000129	0.00139	CcSEcCtD
Valsartan—Urticaria—Sibutramine—obesity	0.000126	0.00135	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Bupropion—obesity	0.000126	0.00135	CcSEcCtD
Valsartan—CYP2C9—endocrine gland—obesity	0.000125	0.0209	CbGeAlD
Valsartan—Abdominal pain—Sibutramine—obesity	0.000125	0.00135	CcSEcCtD
Valsartan—Insomnia—Bupropion—obesity	0.000125	0.00134	CcSEcCtD
Valsartan—Haemoglobin—Topiramate—obesity	0.000124	0.00134	CcSEcCtD
Valsartan—Rhinitis—Topiramate—obesity	0.000124	0.00134	CcSEcCtD
Valsartan—Paraesthesia—Bupropion—obesity	0.000124	0.00134	CcSEcCtD
Valsartan—Hepatitis—Topiramate—obesity	0.000124	0.00133	CcSEcCtD
Valsartan—Haemorrhage—Topiramate—obesity	0.000124	0.00133	CcSEcCtD
Valsartan—Dyspnoea—Bupropion—obesity	0.000123	0.00133	CcSEcCtD
Valsartan—Pharyngitis—Topiramate—obesity	0.000123	0.00132	CcSEcCtD
Valsartan—Somnolence—Bupropion—obesity	0.000123	0.00132	CcSEcCtD
Valsartan—Urinary tract disorder—Topiramate—obesity	0.000122	0.00132	CcSEcCtD
Valsartan—Connective tissue disorder—Topiramate—obesity	0.000122	0.00131	CcSEcCtD
Valsartan—Dyspepsia—Bupropion—obesity	0.000122	0.00131	CcSEcCtD
Valsartan—Urethral disorder—Topiramate—obesity	0.000121	0.00131	CcSEcCtD
Valsartan—Hypersensitivity—Orlistat—obesity	0.000121	0.0013	CcSEcCtD
Valsartan—Decreased appetite—Bupropion—obesity	0.00012	0.00129	CcSEcCtD
Valsartan—Gastrointestinal disorder—Bupropion—obesity	0.000119	0.00128	CcSEcCtD
Valsartan—Fatigue—Bupropion—obesity	0.000119	0.00128	CcSEcCtD
Valsartan—Constipation—Bupropion—obesity	0.000118	0.00127	CcSEcCtD
Valsartan—Asthenia—Orlistat—obesity	0.000117	0.00126	CcSEcCtD
Valsartan—Hypersensitivity—Sibutramine—obesity	0.000117	0.00126	CcSEcCtD
Valsartan—Pruritus—Orlistat—obesity	0.000116	0.00125	CcSEcCtD
Valsartan—Cardiac disorder—Topiramate—obesity	0.000115	0.00124	CcSEcCtD
Valsartan—Asthenia—Sibutramine—obesity	0.000114	0.00122	CcSEcCtD
Valsartan—CYP2C9—liver—obesity	0.000113	0.0188	CbGeAlD
Valsartan—Gastrointestinal pain—Bupropion—obesity	0.000113	0.00122	CcSEcCtD
Valsartan—Angiopathy—Topiramate—obesity	0.000112	0.00121	CcSEcCtD
Valsartan—Pruritus—Sibutramine—obesity	0.000112	0.00121	CcSEcCtD
Valsartan—Diarrhoea—Orlistat—obesity	0.000112	0.00121	CcSEcCtD
Valsartan—Immune system disorder—Topiramate—obesity	0.000112	0.0012	CcSEcCtD
Valsartan—Mediastinal disorder—Topiramate—obesity	0.000112	0.0012	CcSEcCtD
Valsartan—Urticaria—Bupropion—obesity	0.00011	0.00118	CcSEcCtD
Valsartan—Alopecia—Topiramate—obesity	0.000109	0.00118	CcSEcCtD
Valsartan—Abdominal pain—Bupropion—obesity	0.000109	0.00118	CcSEcCtD
Valsartan—Mental disorder—Topiramate—obesity	0.000108	0.00117	CcSEcCtD
Valsartan—Diarrhoea—Sibutramine—obesity	0.000108	0.00117	CcSEcCtD
Valsartan—Dizziness—Orlistat—obesity	0.000108	0.00117	CcSEcCtD
Valsartan—Malnutrition—Topiramate—obesity	0.000108	0.00116	CcSEcCtD
Valsartan—Flatulence—Topiramate—obesity	0.000106	0.00114	CcSEcCtD
Valsartan—Dysgeusia—Topiramate—obesity	0.000106	0.00114	CcSEcCtD
Valsartan—Dizziness—Sibutramine—obesity	0.000105	0.00113	CcSEcCtD
Valsartan—Back pain—Topiramate—obesity	0.000104	0.00112	CcSEcCtD
Valsartan—Vomiting—Orlistat—obesity	0.000104	0.00112	CcSEcCtD
Valsartan—Muscle spasms—Topiramate—obesity	0.000104	0.00112	CcSEcCtD
Valsartan—Rash—Orlistat—obesity	0.000103	0.00111	CcSEcCtD
Valsartan—Dermatitis—Orlistat—obesity	0.000103	0.00111	CcSEcCtD
Valsartan—Headache—Orlistat—obesity	0.000102	0.0011	CcSEcCtD
Valsartan—Hypersensitivity—Bupropion—obesity	0.000102	0.0011	CcSEcCtD
Valsartan—Vision blurred—Topiramate—obesity	0.000102	0.00109	CcSEcCtD
Valsartan—Vomiting—Sibutramine—obesity	0.000101	0.00108	CcSEcCtD
Valsartan—Rash—Sibutramine—obesity	9.98e-05	0.00108	CcSEcCtD
Valsartan—Dermatitis—Sibutramine—obesity	9.97e-05	0.00107	CcSEcCtD
Valsartan—Headache—Sibutramine—obesity	9.92e-05	0.00107	CcSEcCtD
Valsartan—Asthenia—Bupropion—obesity	9.9e-05	0.00107	CcSEcCtD
Valsartan—Pruritus—Bupropion—obesity	9.77e-05	0.00105	CcSEcCtD
Valsartan—Nausea—Orlistat—obesity	9.72e-05	0.00105	CcSEcCtD
Valsartan—Vertigo—Topiramate—obesity	9.68e-05	0.00104	CcSEcCtD
Valsartan—Syncope—Topiramate—obesity	9.66e-05	0.00104	CcSEcCtD
Valsartan—Palpitations—Topiramate—obesity	9.52e-05	0.00103	CcSEcCtD
Valsartan—Loss of consciousness—Topiramate—obesity	9.47e-05	0.00102	CcSEcCtD
Valsartan—Diarrhoea—Bupropion—obesity	9.44e-05	0.00102	CcSEcCtD
Valsartan—Nausea—Sibutramine—obesity	9.4e-05	0.00101	CcSEcCtD
Valsartan—Cough—Topiramate—obesity	9.4e-05	0.00101	CcSEcCtD
Valsartan—Myalgia—Topiramate—obesity	9.17e-05	0.000988	CcSEcCtD
Valsartan—Arthralgia—Topiramate—obesity	9.17e-05	0.000988	CcSEcCtD
Valsartan—Chest pain—Topiramate—obesity	9.17e-05	0.000988	CcSEcCtD
Valsartan—Anxiety—Topiramate—obesity	9.14e-05	0.000985	CcSEcCtD
Valsartan—Dizziness—Bupropion—obesity	9.13e-05	0.000983	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	9.11e-05	0.000981	CcSEcCtD
Valsartan—Dry mouth—Topiramate—obesity	8.97e-05	0.000966	CcSEcCtD
Valsartan—Oedema—Topiramate—obesity	8.79e-05	0.000947	CcSEcCtD
Valsartan—Vomiting—Bupropion—obesity	8.78e-05	0.000945	CcSEcCtD
Valsartan—Infection—Topiramate—obesity	8.74e-05	0.000941	CcSEcCtD
Valsartan—Rash—Bupropion—obesity	8.7e-05	0.000938	CcSEcCtD
Valsartan—Dermatitis—Bupropion—obesity	8.7e-05	0.000937	CcSEcCtD
Valsartan—Shock—Topiramate—obesity	8.65e-05	0.000932	CcSEcCtD
Valsartan—Headache—Bupropion—obesity	8.65e-05	0.000932	CcSEcCtD
Valsartan—Nervous system disorder—Topiramate—obesity	8.62e-05	0.000929	CcSEcCtD
Valsartan—Thrombocytopenia—Topiramate—obesity	8.61e-05	0.000928	CcSEcCtD
Valsartan—Skin disorder—Topiramate—obesity	8.54e-05	0.00092	CcSEcCtD
Valsartan—Anorexia—Topiramate—obesity	8.38e-05	0.000903	CcSEcCtD
Valsartan—Hypotension—Topiramate—obesity	8.22e-05	0.000885	CcSEcCtD
Valsartan—Nausea—Bupropion—obesity	8.2e-05	0.000883	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Topiramate—obesity	8.01e-05	0.000863	CcSEcCtD
Valsartan—Insomnia—Topiramate—obesity	7.95e-05	0.000857	CcSEcCtD
Valsartan—Paraesthesia—Topiramate—obesity	7.9e-05	0.000851	CcSEcCtD
Valsartan—Dyspnoea—Topiramate—obesity	7.84e-05	0.000845	CcSEcCtD
Valsartan—Somnolence—Topiramate—obesity	7.82e-05	0.000842	CcSEcCtD
Valsartan—Dyspepsia—Topiramate—obesity	7.74e-05	0.000834	CcSEcCtD
Valsartan—Decreased appetite—Topiramate—obesity	7.64e-05	0.000824	CcSEcCtD
Valsartan—Gastrointestinal disorder—Topiramate—obesity	7.59e-05	0.000818	CcSEcCtD
Valsartan—Fatigue—Topiramate—obesity	7.58e-05	0.000817	CcSEcCtD
Valsartan—Constipation—Topiramate—obesity	7.52e-05	0.00081	CcSEcCtD
Valsartan—Gastrointestinal pain—Topiramate—obesity	7.19e-05	0.000775	CcSEcCtD
Valsartan—Urticaria—Topiramate—obesity	6.99e-05	0.000753	CcSEcCtD
Valsartan—Abdominal pain—Topiramate—obesity	6.95e-05	0.000749	CcSEcCtD
Valsartan—Hypersensitivity—Topiramate—obesity	6.48e-05	0.000698	CcSEcCtD
Valsartan—Asthenia—Topiramate—obesity	6.31e-05	0.00068	CcSEcCtD
Valsartan—Pruritus—Topiramate—obesity	6.22e-05	0.00067	CcSEcCtD
Valsartan—Diarrhoea—Topiramate—obesity	6.02e-05	0.000648	CcSEcCtD
Valsartan—Dizziness—Topiramate—obesity	5.82e-05	0.000626	CcSEcCtD
Valsartan—Vomiting—Topiramate—obesity	5.59e-05	0.000602	CcSEcCtD
Valsartan—Rash—Topiramate—obesity	5.54e-05	0.000597	CcSEcCtD
Valsartan—Dermatitis—Topiramate—obesity	5.54e-05	0.000597	CcSEcCtD
Valsartan—Headache—Topiramate—obesity	5.51e-05	0.000593	CcSEcCtD
Valsartan—Nausea—Topiramate—obesity	5.22e-05	0.000563	CcSEcCtD
Valsartan—CYP2C9—Metabolism—HSD11B1—obesity	7.01e-06	9.96e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—UCP3—obesity	7.01e-06	9.96e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARA—obesity	7e-06	9.95e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOA5—obesity	6.98e-06	9.92e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—F2—obesity	6.97e-06	9.9e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PRKCB—obesity	6.97e-06	9.9e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CG—obesity	6.96e-06	9.88e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ADH1B—obesity	6.9e-06	9.8e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BAD—obesity	6.88e-06	9.78e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—F2—obesity	6.88e-06	9.78e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PRKCB—obesity	6.88e-06	9.78e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—COMT—obesity	6.88e-06	9.78e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOB—obesity	6.8e-06	9.65e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPAM—obesity	6.79e-06	9.65e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARGC1B—obesity	6.79e-06	9.65e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ACSL1—obesity	6.79e-06	9.65e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARGC1A—obesity	6.79e-06	9.64e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GNB3—obesity	6.79e-06	9.64e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—AGT—obesity	6.78e-06	9.63e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HMOX1—obesity	6.76e-06	9.6e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—obesity	6.71e-06	9.54e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CG—obesity	6.67e-06	9.47e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC22A1—obesity	6.66e-06	9.46e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CLOCK—obesity	6.66e-06	9.46e-05	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—PPARA—obesity	6.66e-06	9.46e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOE—obesity	6.64e-06	9.44e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—POMC—obesity	6.62e-06	9.41e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GNAS—obesity	6.61e-06	9.39e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HADH—obesity	6.59e-06	9.36e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PCK1—obesity	6.59e-06	9.36e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—FADS1—obesity	6.59e-06	9.36e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IRS1—obesity	6.59e-06	9.36e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CG—obesity	6.59e-06	9.36e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—INS—obesity	6.59e-06	9.36e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CAV1—obesity	6.58e-06	9.35e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOA1—obesity	6.57e-06	9.33e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—SULT2A1—obesity	6.49e-06	9.22e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GLP1R—obesity	6.49e-06	9.22e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—obesity	6.49e-06	9.22e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOB—obesity	6.47e-06	9.19e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ACP5—obesity	6.41e-06	9.11e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—DPYD—obesity	6.39e-06	9.07e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—POMC—obesity	6.35e-06	9.02e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—obesity	6.33e-06	8.99e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—INS—obesity	6.31e-06	8.97e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—G6PD—obesity	6.25e-06	8.88e-05	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—APOA1—obesity	6.25e-06	8.87e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL2—obesity	6.21e-06	8.82e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—LPL—obesity	6.18e-06	8.78e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HK1—obesity	6.17e-06	8.77e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SREBF2—obesity	6.17e-06	8.77e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CD36—obesity	6.17e-06	8.76e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PRKAR2B—obesity	6.15e-06	8.73e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CD—obesity	6.12e-06	8.69e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF1—obesity	6.1e-06	8.67e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—DCN—obesity	6.1e-06	8.67e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT2—obesity	6.1e-06	8.67e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—obesity	6.04e-06	8.58e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF1—obesity	6.03e-06	8.57e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GPX1—obesity	6.03e-06	8.56e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT2—obesity	6.03e-06	8.56e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CG—obesity	6e-06	8.52e-05	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CA—obesity	5.97e-06	8.48e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPA—obesity	5.96e-06	8.47e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CPT1A—obesity	5.94e-06	8.43e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CD36—obesity	5.87e-06	8.34e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CD—obesity	5.86e-06	8.33e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPIN1—obesity	5.83e-06	8.29e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NAMPT—obesity	5.82e-06	8.27e-05	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CA—obesity	5.81e-06	8.25e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SERPINE1—obesity	5.8e-06	8.24e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CD—obesity	5.79e-06	8.23e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—obesity	5.79e-06	8.22e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GCK—obesity	5.79e-06	8.22e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—LIPC—obesity	5.79e-06	8.22e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3R1—obesity	5.78e-06	8.2e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NOS3—obesity	5.78e-06	8.2e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOC3—obesity	5.75e-06	8.17e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—obesity	5.73e-06	8.14e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SERPINE1—obesity	5.73e-06	8.14e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA5—obesity	5.71e-06	8.12e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—POMC—obesity	5.71e-06	8.11e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TYK2—obesity	5.64e-06	8.01e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RHOA—obesity	5.59e-06	7.94e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CETP—obesity	5.58e-06	7.93e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MTHFR—obesity	5.56e-06	7.9e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—obesity	5.55e-06	7.89e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOS3—obesity	5.53e-06	7.86e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3R1—obesity	5.53e-06	7.86e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RHOA—obesity	5.53e-06	7.85e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—SDC1—obesity	5.52e-06	7.84e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS3—obesity	5.47e-06	7.77e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3R1—obesity	5.47e-06	7.77e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARA—obesity	5.46e-06	7.75e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC22A1—obesity	5.45e-06	7.75e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CLOCK—obesity	5.45e-06	7.75e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—obesity	5.44e-06	7.73e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKR1C3—obesity	5.43e-06	7.71e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—obesity	5.39e-06	7.66e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—obesity	5.38e-06	7.64e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—SCARB1—obesity	5.35e-06	7.59e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CB—obesity	5.33e-06	7.57e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SULT2A1—obesity	5.31e-06	7.55e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GLP1R—obesity	5.31e-06	7.55e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AGT—obesity	5.29e-06	7.51e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—obesity	5.28e-06	7.5e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CD—obesity	5.27e-06	7.49e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CA—obesity	5.27e-06	7.49e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—DPYD—obesity	5.23e-06	7.43e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—SREBF1—obesity	5.19e-06	7.37e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOE—obesity	5.18e-06	7.36e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CAV1—obesity	5.13e-06	7.29e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOA1—obesity	5.12e-06	7.27e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CB—obesity	5.11e-06	7.26e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MTOR—obesity	5.11e-06	7.26e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GOT2—obesity	5.05e-06	7.17e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CB—obesity	5.05e-06	7.17e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PRKAR2B—obesity	5.03e-06	7.15e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—DCN—obesity	5e-06	7.1e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3R1—obesity	4.98e-06	7.07e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—FASN—obesity	4.94e-06	7.02e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—BCHE—obesity	4.92e-06	6.99e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—obesity	4.91e-06	6.97e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—obesity	4.9e-06	6.97e-05	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—obesity	4.88e-06	6.93e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CPT1A—obesity	4.86e-06	6.9e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NAMPT—obesity	4.77e-06	6.77e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2E1—obesity	4.75e-06	6.74e-05	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—obesity	4.74e-06	6.74e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—obesity	4.74e-06	6.73e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LIPC—obesity	4.74e-06	6.73e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GCK—obesity	4.74e-06	6.73e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOC3—obesity	4.71e-06	6.69e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NQO1—obesity	4.69e-06	6.67e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CG—obesity	4.67e-06	6.64e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—obesity	4.67e-06	6.64e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—obesity	4.67e-06	6.63e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CB—obesity	4.6e-06	6.53e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CETP—obesity	4.57e-06	6.49e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—obesity	4.55e-06	6.47e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SDC1—obesity	4.52e-06	6.42e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—obesity	4.51e-06	6.41e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GCG—obesity	4.5e-06	6.39e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC2A4—obesity	4.5e-06	6.39e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—POMC—obesity	4.45e-06	6.32e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKR1C3—obesity	4.44e-06	6.31e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYCS—obesity	4.44e-06	6.31e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—obesity	4.44e-06	6.31e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—INS—obesity	4.42e-06	6.29e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SCARB1—obesity	4.38e-06	6.22e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GOT1—obesity	4.36e-06	6.19e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GGT1—obesity	4.36e-06	6.19e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK8—obesity	4.32e-06	6.14e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—obesity	4.32e-06	6.13e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—obesity	4.31e-06	6.12e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOA1—obesity	4.29e-06	6.1e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—obesity	4.26e-06	6.05e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SREBF1—obesity	4.25e-06	6.03e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP19A1—obesity	4.23e-06	6.01e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—STK11—obesity	4.23e-06	6.01e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GOT2—obesity	4.13e-06	5.87e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CD—obesity	4.11e-06	5.84e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—obesity	4.07e-06	5.79e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—obesity	4.06e-06	5.76e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—FASN—obesity	4.04e-06	5.74e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—BCHE—obesity	4.03e-06	5.72e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT3—obesity	3.95e-06	5.61e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—COMT—obesity	3.93e-06	5.59e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2E1—obesity	3.88e-06	5.52e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NOS3—obesity	3.88e-06	5.51e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3R1—obesity	3.88e-06	5.51e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARGC1A—obesity	3.88e-06	5.51e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GNB3—obesity	3.88e-06	5.51e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMOX1—obesity	3.86e-06	5.48e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NQO1—obesity	3.84e-06	5.46e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GNAS—obesity	3.78e-06	5.36e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—obesity	3.76e-06	5.34e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—obesity	3.73e-06	5.29e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOB—obesity	3.7e-06	5.25e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GCG—obesity	3.68e-06	5.23e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC2A4—obesity	3.68e-06	5.23e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MYC—obesity	3.67e-06	5.21e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—obesity	3.66e-06	5.2e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYCS—obesity	3.63e-06	5.16e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—obesity	3.62e-06	5.14e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CB—obesity	3.58e-06	5.09e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GGT1—obesity	3.57e-06	5.07e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GOT1—obesity	3.57e-06	5.07e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—obesity	3.55e-06	5.04e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—LPL—obesity	3.53e-06	5.02e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOA1—obesity	3.51e-06	4.99e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—STK11—obesity	3.46e-06	4.92e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP19A1—obesity	3.46e-06	4.92e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPX1—obesity	3.44e-06	4.89e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CD36—obesity	3.35e-06	4.77e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CA—obesity	3.25e-06	4.62e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—COMT—obesity	3.22e-06	4.57e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTHFR—obesity	3.18e-06	4.52e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARGC1A—obesity	3.17e-06	4.51e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GNB3—obesity	3.17e-06	4.51e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMOX1—obesity	3.16e-06	4.49e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARA—obesity	3.12e-06	4.43e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CA—obesity	3.11e-06	4.42e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GNAS—obesity	3.09e-06	4.39e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CA—obesity	3.08e-06	4.37e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOB—obesity	3.03e-06	4.3e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AGT—obesity	3.02e-06	4.29e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOE—obesity	2.96e-06	4.2e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CAV1—obesity	2.93e-06	4.17e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOA1—obesity	2.93e-06	4.16e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPL—obesity	2.89e-06	4.11e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX1—obesity	2.82e-06	4.01e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CA—obesity	2.8e-06	3.98e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—obesity	2.76e-06	3.92e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CD36—obesity	2.75e-06	3.9e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CG—obesity	2.67e-06	3.79e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—obesity	2.65e-06	3.77e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTHFR—obesity	2.6e-06	3.7e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—obesity	2.58e-06	3.66e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARA—obesity	2.55e-06	3.63e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—obesity	2.54e-06	3.61e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—POMC—obesity	2.54e-06	3.61e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—INS—obesity	2.53e-06	3.59e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—obesity	2.51e-06	3.57e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AGT—obesity	2.47e-06	3.51e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOE—obesity	2.42e-06	3.44e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CAV1—obesity	2.4e-06	3.41e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA1—obesity	2.39e-06	3.4e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CD—obesity	2.35e-06	3.34e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—obesity	2.29e-06	3.26e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3R1—obesity	2.22e-06	3.15e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NOS3—obesity	2.22e-06	3.15e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CG—obesity	2.19e-06	3.11e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CA—obesity	2.18e-06	3.1e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—obesity	2.11e-06	3e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—POMC—obesity	2.08e-06	2.96e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—INS—obesity	2.07e-06	2.94e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CB—obesity	2.05e-06	2.91e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—obesity	2.03e-06	2.88e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CD—obesity	1.92e-06	2.73e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—obesity	1.9e-06	2.7e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3R1—obesity	1.81e-06	2.58e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NOS3—obesity	1.81e-06	2.58e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—obesity	1.78e-06	2.53e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CB—obesity	1.68e-06	2.38e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—obesity	1.66e-06	2.36e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CA—obesity	1.25e-06	1.77e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CA—obesity	1.02e-06	1.45e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—obesity	1.02e-06	1.45e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—obesity	8.34e-07	1.19e-05	CbGpPWpGaD
